{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:00:28Z","timestamp":1783033228449,"version":"3.54.6"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Politecnica delle Marche"},{"name":"Ricerca di Ateneo to Riccardo Sarzani"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Data on the safety of inclisiran, a lipid-lowering small interfering RNA (siRNA) inhibiting proprotein convertase subtilisin\/kexin type 9 (PCSK9) secretion, during pregnancy are absent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 30-year-old woman suffering from heterozygous familial hypercholesterolaemia started treatment with inclisiran 25 weeks before the start of gestation and received a second administration 13 weeks before the start of gestation. As soon as we became aware of the unplanned pregnancy, given the absence of any data regarding the administration of inclisiran during this period, the treatment was discontinued and the pregnancy was closely monitored. After a normal and full-term gestation, birth occurred at 41 + 0 gestational weeks. The baby was female and healthy, with normal anthropometry for her gestational age; her growth and development in the first 8 months of life followed a normal course.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Potential harms to the foetus with systemic malformations have been highlighted with the genetically proxied LDL cholesterol lowering through PCSK9. To the best of our knowledge, this is the first case of pregnancy initiated few months after inclisiran administration, without reporting any adverse effect on the patient or the baby. More data are needed on the pharmacodynamics and safety of siRNAs in general, and of inclisiran in particular, to confirm that this drug could be safe even in this specific setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytaf061","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:39:26Z","timestamp":1740130766000},"source":"Crossref","is-referenced-by-count":1,"title":["Pregnancy 3 months after inclisiran injection: a unique case report including newborn baby monitoring"],"prefix":"10.1093","volume":"9","author":[{"given":"Massimiliano","family":"Allevi","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Sciences, University \u2018Politecnica delle Marche\u2019 , 60020 Ancona ,","place":["Italy"]},{"name":"Unit of Post-Acute Care, IRCCS INRCA , 60127 Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Landolfo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, University \u2018Politecnica delle Marche\u2019 , 60020 Ancona ,","place":["Italy"]},{"name":"Internal Medicine and Geriatrics, \u2018Hypertension Excellence Centre\u2019 of the European Society of Hypertension, Societ\u00e0 Italiana per lo Studio dell'Aterosclerosi (SISA) LIPIGEN Centre, IRCCS INRCA , 60127 Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Giulietti","sequence":"additional","affiliation":[{"name":"Internal Medicine and Geriatrics, \u2018Hypertension Excellence Centre\u2019 of the European Society of Hypertension, Societ\u00e0 Italiana per lo Studio dell'Aterosclerosi (SISA) LIPIGEN Centre, IRCCS INRCA , 60127 Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-7819","authenticated-orcid":false,"given":"Francesco","family":"Spannella","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, University \u2018Politecnica delle Marche\u2019 , 60020 Ancona ,","place":["Italy"]},{"name":"Internal Medicine and Geriatrics, \u2018Hypertension Excellence Centre\u2019 of the European Society of Hypertension, Societ\u00e0 Italiana per lo Studio dell'Aterosclerosi (SISA) LIPIGEN Centre, IRCCS INRCA , 60127 Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Sarzani","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, University \u2018Politecnica delle Marche\u2019 , 60020 Ancona ,","place":["Italy"]},{"name":"Internal Medicine and Geriatrics, \u2018Hypertension Excellence Centre\u2019 of the European Society of Hypertension, Societ\u00e0 Italiana per lo Studio dell'Aterosclerosi (SISA) LIPIGEN Centre, IRCCS INRCA , 60127 Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"2025022113511528000_ytaf061-B1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2025022113511528000_ytaf061-B2","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2025022113511528000_ytaf061-B3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/ijms25010328","article-title":"Molecular therapies in cardiovascular diseases: small interfering RNA in atherosclerosis, heart failure, and hypertension","volume":"25","author":"Sarzani","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025022113511528000_ytaf061-B4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00008480-200312000-00011","article-title":"Human malformation syndromes due to inborn errors of cholesterol synthesis","volume":"15","author":"Porter","year":"2003","journal-title":"Curr Opin Pediatr"},{"key":"2025022113511528000_ytaf061-B5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12944-016-0365-6","article-title":"Fetal gender and gestational age differentially affect PCSK9 levels in intrauterine growth restriction","volume":"15","author":"Pecks","year":"2016","journal-title":"Lipids Health Dis"},{"key":"2025022113511528000_ytaf061-B6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40264-017-0616-0","article-title":"Using human \u2018experiments of nature\u2019 to predict drug safety issues: an example with PCSK9 inhibitors","volume":"41","author":"Jerome","year":"2018","journal-title":"Drug Saf"},{"key":"2025022113511528000_ytaf061-B7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/eurjpc\/zwad402","article-title":"Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations","volume":"31","author":"Ardissino","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025022113511528000_ytaf061-B8","article-title":"Dyslipidaemia management in pregnant patients: a 2024 update","volume":"4","author":"Lewek","year":"2024","journal-title":"Eur Hear J open"},{"key":"2025022113511528000_ytaf061-B9","doi-asserted-by":"crossref","first-page":"1181720","DOI":"10.3389\/fcvm.2023.1181720","article-title":"Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report","volume":"10","author":"Allevi","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2025022113511528000_ytaf061-B10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc England"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/2\/ytaf061\/62042774\/ytaf061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/2\/ytaf061\/62042774\/ytaf061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:51:32Z","timestamp":1740145892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytaf061\/8029325"}},"subtitle":[],"editor":[{"given":"David","family":"Oxborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Marie-Luise","family":"Dikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Stefania Angela","family":"Di Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytaf061","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2,1]]},"article-number":"ytaf061"}}